Makes Traditional Chinese Medicine products for hospitals and patients in China.
Mar 2026Revenue $1.14M/yrExpenses $8.26M/yr
Fell below break-even Oct 2019Cash runway ≈ 7.0 years from Mar 2026
Figures by year
When will China SXT Pharmaceuticals be profitable again?
Its expenses passed its revenue in Oct 2019. In the 12 months to Mar 2026, revenue was $1.14M and expenses $8.26M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Mar 2026 | $1.14M | $8.26M | −$7.12M |
| Mar 2025 | $1.74M | $4.42M | −$2.68M |
| Mar 2024 | $1.93M | $4.44M | −$2.52M |
| Mar 2023 | $1.97M | $7.58M | −$5.61M |
| Mar 2022 | $2.60M | $7.79M | −$5.19M |
| Mar 2021 | $4.78M | $6.97M | −$2.20M |
| Mar 2020 | $5.16M | $6.50M | −$1.34M |
| Mar 2019 | $7.01M | $5.24M | $1.77M |
| Mar 2018 | $7.02M | $5.39M | $1.63M |
| Mar 2017 | $4.88M | $3.28M | $1.60M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.